Loxo Oncology (LOXO) Reports Q2 Loss of $1.64, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Loxo Oncology Reports Second Quarter 2018 Financial Results
August 9, 2018 6:45 AM EDT- LOXO-292 New Drug Application (NDA) Submission to FDA Expected in Late 2019 -
- Updated Larotrectinib Duration of Response Data to be Reported at ESMO -
- Larotrectinib NDA PDUFA date is November 26, 2018 -
STAMFORD, Conn., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today reported second quarter 2018 financial results.
We made significant progress across our pipeline in the second quarter, said Josh... More
